Dynavax Technologies Corporation (NASDAQ:DVAX) is a good case in point. The company's Heplisav hepatitis B vaccine looked good in clinical trials when compared to the leading vaccine on the market.
Dynavax Technologies Corp (NASDAQ: DVAX) reported Q1 EPS of ($0.11), in-line with the analyst estimate of ($0.11). For the quarter ended March 31, 2013, Dynavax reported total revenues of $2.1 million compared to $2.4 million for the quarter ended ...
New York, NY -- (SBWIRE) -- 04/28/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Dynavax Technologies Corporation (NASDAQ:DVAX), Nanosphere, Inc. (NASDAQ:NSPH), and Delcath Systems, Inc.
Dynavax Technologies Corporation (NASDAQ:DVAX) a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases is currently down (-3.20%) on 897,308 shares traded.
New York, NY - (NISMAGAZINE) - 05/05/2013- Dynavax Technologies Corporation (NASDAQ:DVAX) shows bullish trend since it made an upward movement of 5.48% with trading volume of 1.34 million shares, in contrast to the 30 days average daily trading ...
New York, NY - (NISMAGAZINE) - 04/26/2013- Dynavax Technologies Corporation (NASDAQ:DVAX) plunged by 4.00% after opening at $2.92, throughout the stock traded in a band of $2.42 and $2.48.
New York, NY - (NISMAGAZINE) - 04/28/2013- Cincinnati Bell Inc. (NYSE:CBB) plunged 3.07% and closed to $3.47. The stock recorded the volume of 1.56 million shares.
Dynavax Technologies Corporation(NASDAQ:DVAX) ended higher 2.89% and completed the day at $2.49. The total number of shares that changed hands during the day was 1.99 million.
Dynavax Technologies Corporation ( DVAX ) suffered a loss of 11 cents per share in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 10 cents per share but flat year over year.
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. To see all exchange delays, please see disclaimer.